Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MHY1485 is a mTOR activator. It inhibits the autophagic process by inhibition of fusion between autophagosomes and lysosomes, leading to the accumulation of LC3II protein and enlarged autophagosomes.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
5 mg | 在庫あり | ¥ 10,000 | |||
10 mg | 在庫あり | ¥ 14,000 | |||
25 mg | 在庫あり | ¥ 26,000 | |||
50 mg | 在庫あり | ¥ 45,000 | |||
100 mg | 在庫あり | ¥ 83,500 | |||
200 mg | お問い合わせ | ¥ 123,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 11,000 |
説明 | MHY1485 is a mTOR activator. It inhibits the autophagic process by inhibition of fusion between autophagosomes and lysosomes, leading to the accumulation of LC3II protein and enlarged autophagosomes. |
In vivo | MHY1485 elevates the phosphorylation levels of mTOR and its downstream targets, S6K1 and rpS6 proteins, without affecting the total content of mTOR, S6K1, and rpS6. Short-term treatment with MHY1485 before xenotransplantation of ovaries can promote the growth of secondary hair follicles. Additionally, post-treatment transplantation with MHY1485 facilitates the generation of mature oocytes and the production of healthy offspring. MHY1485 induces the accumulation of LC3II and the expansion of autophagosomes in a dose- and time-dependent manner. |
キナーゼ試験 | Ovaries from mice at day10 of age are treated with 10 μM MHY1485 for 3h and proteins are extracted using M-PER Mammalian Protein Extraction Reagent containing a protease inhibitor cocktail. Protein concentrations in supernatants are determined by the bicinchoninic acid method. Equal amounts of protein lysates are loaded on 4-12% NuPAGE Bis-Tris gels in MOPS buffer and transferred to 0.45 μM pore nitrocellulose membranes[2]. |
細胞研究 | MHY1485 is dissolved in DMSO and then diluted with appropriate media[3]. MC3T3-E1 cells are maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin and 100 mg/mL streptomycin at 37°C in a humidified atmosphere of 5% CO2. Having reached 70% confluence, the culture medium is switched to commercial osteogenic differentiation medium. MC3T3-E1 cells are cultured in the osteogenic differentiation medium for 14 days, following by culture in DMEM supplemented with varying concentrations of liraglutide (catalog no. HY-P0014; MedChem Express) for a further 14 days. MC3T3-E1 cells treated with 4 nM liraglutide are cultured in the presence or absence of Compound C or MHY1485. MC3T3-E1 cells maintained in DMEM for 28 days in the absence of any treatment are used as the negative control (NC); cells cultured in commercial osteogenic differentiation medium for 14 days and in DMEM without liraglutide for an additional 14 days are used as the positive control (PC)[3]. |
分子量 | 387.39 |
分子式 | C17H21N7O4 |
CAS No. | 326914-06-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 3.87 mg/mL (10 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
MHY1485 326914-06-1 Autophagy PI3K/Akt/mTOR signaling mTOR cell MC3T3-E1 FSH MHY 1485 Inhibitor cell-permeable Mammalian target of Rapamycin inhibit MHY-1485 inhibitor